Dubey Raghvendra K, Gillespie Delbert G, Zacharia Lefteris C, Rosselli Marinella, Imthurn Bruno, Jackson Edwin K
Department of Obstetrics and Gynecology, Clinic for Endocrinology, University Hospital Zurich, Switzerland.
Hypertension. 2002 Feb;39(2 Pt 2):412-7. doi: 10.1161/hy0202.102837.
Estradiol inhibits cardiac fibroblast growth and may protect against cardiac remodeling associated with heart disease. However, the mechanisms by which estradiol attenuates cardiac fibroblast growth remain unclear. Because cardiac fibroblasts express cytochrome P450s (CYP450s) and catechol-O-methyltransferase (COMT) capable of converting estradiol to hydroxyestradiols and methoxyestradiols, respectively, and because hydroxyestradiols and methoxyestradiols (estradiol metabolites with little affinity for estrogen receptors) are potent inhibitors of cardiac fibroblast growth, we hypothesized that the antimitogenic effects of estradiol are mediated via hydroxyestradiols and/or methoxyestradiols. The inhibitory effects of estradiol (1 to 100 nmol/L) on serum-stimulated (3)H-thymidine incorporation (DNA synthesis), (3)H-proline incorporation (collagen synthesis), and cell number (proliferation) were enhanced (P<0.005) by CYP450 inducers 3-methylcholanthrene (10 micromol/L) and phenobarbital (10 micromol/L). Moreover, the inhibitory effects of estradiol were blocked by the CYP450 inhibitor 1-aminobenzotriazole (10 micromol/L) and the COMT inhibitors quercetin (10 micromol/L) and OR486 (10 micromol/L). In contrast to estradiol, the modulators of CYP450 and COMT were poor ligands for estrogen receptors (binding affinity less-than-or-equal 0.0001% versus estradiol). In cardiac fibroblasts, both quercetin and OR486 inhibited the metabolism of hydroxyestradiol to methoxyestradiol and blocked the inhibitory effects of hydroxyestradiol on cardiac fibroblast proliferation and DNA and collagen synthesis. The abrogating effects of quercetin and OR486 on the metabolism and antimitogenic effects of 2-hydroxyestradiol were mimicked by 20 micromol/L norepinephrine and isoproterenol, substrates for COMT. Our findings provide evidence that estradiol can inhibit cardiac fibroblast growth via an estrogen receptor--independent pathway that involves the local metabolism of estradiol to methoxyestradiols.
雌二醇可抑制心脏成纤维细胞生长,并可能预防与心脏病相关的心脏重塑。然而,雌二醇减弱心脏成纤维细胞生长的机制仍不清楚。由于心脏成纤维细胞表达细胞色素P450(CYP450)和儿茶酚-O-甲基转移酶(COMT),它们分别能够将雌二醇转化为羟基雌二醇和甲氧基雌二醇,并且由于羟基雌二醇和甲氧基雌二醇(对雌激素受体亲和力很小的雌二醇代谢产物)是心脏成纤维细胞生长的有效抑制剂,我们推测雌二醇的抗增殖作用是通过羟基雌二醇和/或甲氧基雌二醇介导的。CYP450诱导剂3-甲基胆蒽(10 μmol/L)和苯巴比妥(10 μmol/L)增强了雌二醇(1至100 nmol/L)对血清刺激的[3H]胸腺嘧啶掺入(DNA合成)、[3H]脯氨酸掺入(胶原蛋白合成)和细胞数量(增殖)的抑制作用(P<0.005)。此外,雌二醇的抑制作用被CYP450抑制剂1-氨基苯并三唑(10 μmol/L)以及COMT抑制剂槲皮素(10 μmol/L)和OR486(10 μmol/L)阻断。与雌二醇相反,CYP450和COMT的调节剂是雌激素受体的不良配体(结合亲和力≤0.0001%,相对于雌二醇)。在心脏成纤维细胞中,槲皮素和OR486均抑制羟基雌二醇向甲氧基雌二醇的代谢,并阻断羟基雌二醇对心脏成纤维细胞增殖以及DNA和胶原蛋白合成的抑制作用。20 μmol/L去甲肾上腺素和异丙肾上腺素(COMT的底物)模拟了槲皮素和OR486对2-羟基雌二醇代谢和抗增殖作用的消除作用。我们的研究结果提供了证据,表明雌二醇可通过一条不依赖雌激素受体的途径抑制心脏成纤维细胞生长,该途径涉及雌二醇向甲氧基雌二醇的局部代谢。